Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output. That's because earnings are very often less ...

We have reiterated our Neutral recommendation on Cyberonics Inc. (CYBX) with a target price of $46.00, following our assessment of its fourth quarter and fiscal 2012 results. Cyberonics reported ...

Cyberonics Inc., maker of a device to treat epilepsy and depression, said Monday that two top executives had resigned after an investigation revealed errors in its accounting practices. Chief ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: The ...

NEW YORK (AP) -- Shares of Cyberonics Inc. rose Monday on news that a former employee had dropped his lawsuit against the neurological device maker. THE SPARK: Cyberonics said that Andrew Hagerty ...

Cyberonics officials on Thursday said the Houston-based company could begin offering a more sophisticated version of its nerve-stimulating device to treat U.S. epilepsy patients as early as next year, ...

On Sep 15, 2015, we issued an updated research report on Cyberonics Inc. CYBX – a Texas-based medical technology company with core expertise in neuromodulation. While it eagerly awaits the completion ...

Look here for a clue. There's no foolproof way to know the future for Cyberonics (Nasdaq: CYBX) or any other company. However, certain clues may help you see potential stumbles before they happen -- ...

— -- A: Cyberonics makes medical devices that are implanted to control disorders such as epilepsy and some forms of depression. Depending on when you bought this stock, you are probably either ...

Cyberonics has hired a new chief executive from Boston Scientific, the medical instruments and supplies company that owns 14 percent of the Houston company's shares. Daniel Moore, who took over today, ...

So much for efficient markets. Even though Cyberonics' (NASDAQ:CYBX) management had been telling investors for some time that an eventual launch of a therapy for treatment-resistant depression would ...